Nicholas J. Shaheen, Eugene Stuart, Sarah M. Schmitz, Kate L. Mitchell, Michael W. Fried, Steven Zacks, Mark W. Russo, Joseph Galanko, Roshan Shrestha – 22 February 2005 – Elective esophageal variceal ligation (EVL) is performed to decrease the risk of variceal hemorrhage. Side effects of EVL include hemorrhage, chest pain, dysphagia, and odynophagia. Because gastric acid may exacerbate postbanding ulcers and delay healing, proton pump inhibition may decrease side effects associated with EVL.

Joaquin de la Peña, Enric Brullet, Eloy Sanchez‐Hernández, Monserrat Rivero, Mercedes Vergara, Jose Luis Martin‐Lorente, Covadonga Garcia Suárez – 22 February 2005 – β‐Blockers and endoscopic variceal ligation (EVL) have proven to be valuable methods in the prevention of variceal rebleeding. The aim of this study was to compare the efficacy of EVL combined with nadolol versus EVL alone as secondary prophylaxis for variceal bleeding. Patients admitted for acute variceal bleeding were treated during emergency endoscopy with EVL or sclerotherapy and received somatostatin for 5 days.

Kumiko Isse, Kenichi Harada, Yoh Zen, Takashi Kamihira, Shinji Shimoda, Mine Harada, Yasuni Nakanuma – 22 February 2005 – Fractalkine is a chemokine with both chemoattractant and cell‐adhesive functions, and in the intestine it is involved with its receptor CX3CR1 in the chemoattraction and recruitment of intraepithelial lymphocytes. We examined the pathophysiological roles of fractalkine and CX3CR1 in normal and diseased bile ducts.

Karin Dilger, Annette Denk, Malte H. J. Heeg, Ulrich Beuers – 22 February 2005 – Induction of cytochrome P450 3A (CYP3A) has been suggested as a mechanism of action of ursodeoxycholic acid (UDCA) in cholestasis. CYP3A is of key importance in human drug metabolism, being involved in presystemic extraction of more than 50% of all drugs currently available and of various endogenous compounds. Therefore, we compared the induction potential of UDCA with that of the prototypical inducer rifampicin in a human model study with the CYP3A substrates budesonide and cortisol.

Anne‐Laure Sérandour, Pascal Loyer, Delphine Garnier, Brice Courselaud, Nathalie Théret, Denise Glaise, Christiane Guguen‐Guillouzo, Anne Corlu – 22 February 2005 – During liver regeneration, hepatocytes proliferate under the control of both proinflammatory cytokines such as tumor necrosis factor α (TNFα) and growth factors, in parallel to extracellular matrix remodeling. This study investigated mechanisms by which mitogen and extracellular matrix signals are linked for inducing proliferation of differentiated hepatocytes.

Axel Ulsenheimer, J. Tilman Gerlach, Maria‐Christina Jung, Norbert Gruener, Martin Wächtler, Markus Backmund, Teresa Santantonio, Winfried Schraut, Malte H. J. Heeg, Carl A. Schirren, Reinhart Zachoval, Gerd R. Pape, Helmut M. Diepolder – 22 February 2005 – Chronic evolution of acute hepatitis C (aHC) occurs in more than 80% of patients but can frequently be prevented by early treatment with interferon (IFN)‐α. Plasmacytoid dendritic cells (pDCs) are the major endogenous IFN‐α producers, but their role in aHC is unknown.

Teh‐Ia Huo, Yi‐Hsiang Huang – 22 February 2005

Reiner Wiest, Guadalupe Garcia‐Tsao – 22 February 2005 – Gut flora and bacterial translocation (BT) play an important role in the pathogenesis of the complications of cirrhosis. Research on the pathogenesis of BT and its clinical significance transcends established boundaries between microbiology, cell biology, intestinal pathophysiology, and immunology. This review delineates multiple mechanisms involved in the process of BT, with an emphasis on alterations in intestinal flora and mucosal barrier function, particularly immunological defense mechanisms.

Didier Samuel – 22 February 2005

Anja M. Hafkamp, Rick Havinga, Maarten Sinaasappel, Henkjan J. Verkade – 22 February 2005 – We sought to develop an oral treatment for unconjugated hyperbilirubinemia. In the Gunn rat model of unconjugated hyperbilirubinemia, dietary supplementation with the lipase inhibitor orlistat (Orl) or with calcium phosphate (CaP) decreases plasma unconjugated bilirubin (UCB) levels. We determined whether Orl, CaP, or their combination is superior to phototherapy, the conventional treatment, and whether the effects of Orl and CaP are influenced by dietary fat content.